Myxoid liposarcoma associated with adalimumab treatment: A case report

Rodríguez-Cerdeira,Carmen; Neissa-Vasquez,José  Ignacio; Carnero-Gregorio,Miguel; Fiaño-Valverde,Concepción; Muñoz-Garzón,Victor

doi:10.3892/mco.2019.1817

April-2019 Volume 10 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

April-2019 Volume 10 Issue 4

Full Size Image

Case Report

Myxoid liposarcoma associated with adalimumab treatment: A case report

Authors:
- Carmen Rodríguez-Cerdeira
- José Ignacio Neissa-Vasquez
- Miguel Carnero-Gregorio
- Concepción Fiaño-Valverde
- Victor Muñoz-Garzón
View Affiliations / Copyright

Affiliations: Efficiency, Quality and Costs in Health Services Research Group (EFISALUD), Health Research Institute, SERGAS-UVIGO, 36200 Vigo, Spain, Department of Histopathology, Álvaro Cunqueiro Hospital, CHUVI, 36312 Vigo, Spain, Department of Radiotherapy, Meixoeiro Hospital, CHUVI, 36200 Vigo, Spain
Pages: 454-456
|
Published online on: February 27, 2019

https://doi.org/10.3892/mco.2019.1817
Expand metrics +

Abstract

Biological agents that suppress inflammation, such as tumour necrosis factor (TNF-α) inhibitors, are being successfully used at an increasing frequency for the treatment of chronic inflammatory diseases, such as psoriasis. However, these drugs are not free of side effects, and although the general rates of malignancy in patients using anti-TNF-α therapies are not high, certain tumours of cutaneous origin, particularly carcinomas, have been reported. We herein present the case of a 47-year-old female patient with moderate-to-severe psoriasis for 20 years under treatment with adalimumab administered at the standard dose of 40 mg, injected subcutaneously each fortnight, with good efficacy. To the best of our knowledge, this is the first reported case of a low-grade (grade 1) myxoid liposarcoma in a patient receiving treatment with adalimumab since 2009. A review of the relevant literature was also conducted. Continuous investigation of such cases is crucial in order to elucidate the iatrogenic risk of rare cancers, such as myxoid liposarcoma, in patients undergoing treatment with currently available as well as future biological therapies.

View Figures

View References

1	Augustin M, Langenbruch A, Gutknecht M, Reich K, Körber A, Maaßen D, Mrowietz U, Thaçi D, von Kiedrowski R and Radtke MA: Definition of psoriasis severity in routine clinical care: Current guidelines fail to capture the complexity of long-term psoriasis management. Br J Dermatol. 179:1385–1391. 2018. View Article : Google Scholar : PubMed/NCBI
2	Carrera CG, Dapavo P, Malagoli P, Naldi L, Arancio L, Gaiani F, Egan CG, Di Mercurio M and Cattaneo A: PACE study: Real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis. J Dermatolog Treat. 29:481–486. 2018. View Article : Google Scholar : PubMed/NCBI
3	Billi AC and Gudjonsson JE: Adalimumab in Psoriasis: How much is enough? J Invest Dermatol. 139:19–22. 2019. View Article : Google Scholar : PubMed/NCBI
4	Esposito M, Prignano F, Rongioletti F, Hansel K, Bianchi L, Pescitelli L, Lazzeri L, Ricceri F, Mugheddu C, Bavetta M, et al: Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: Clinician behavior in real life clinical practice. J Dermatolog Treat. 6:1–5. 2018. View Article : Google Scholar
5	Ruiz V, Velásquez M and Barrera LF: Immunogenetic aspects of psoriasis with emphasis on micro-RNA. Inmunol. 33:137–146. 2014.
6	Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A and Gelfand JM: The risk of cancer in patients with psoriasis: A population-based cohort study in the health improvement network. JAMA Dermatol. 152:282–290. 2016. View Article : Google Scholar : PubMed/NCBI
7	Rønholt K and Iversen L: Old and new biological therapies for psoriasis. Int J Mol Sci. 18(pii): E22972017. View Article : Google Scholar : PubMed/NCBI
8	Farshid G, Prowse P and True B: Epithelioid myxofibrosarcoma developing at the injection site of Adalimumab therapy for psoriatic synovitis. Eur J Rheumatol. 5:131–134. 2018. View Article : Google Scholar : PubMed/NCBI
9	Krishna SM and Kim CN: Merkel cell carcinoma in a patient treated with adalimumab: Case report. Cutis. 87:81–84. 2011.PubMed/NCBI
10	Amadu V, Satta R, Montesu MA and Cottoni F: Kaposi's sarcoma associated with treatment with adalimumab. Dermatol Ther (Heidelb). 25:619–620. 2012. View Article : Google Scholar
11	Bret J, Hernandez J, Aquilina C, Zabraniecki L and Fournie B: Kaposi's disease in a patient on adalimumab for rheumatoid arthritis. Joint Bone Spine. 76:721–722. 2009. View Article : Google Scholar : PubMed/NCBI
12	Bonovas S, Minozzi S, Lytras T, González-Lorenzo M, Pecoraro V, Colombo S, Polloni I, Moja L, Cinquini M, Marino V, et al: Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: A systematic review and meta-analysis. Expert Opin Drug Saf. 15 (Suppl 1):35–54. 2016. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Myxoid liposarcoma associated with adalimumab treatment: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles